Multiple Sclerosis International最新文献_第8页

Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis? 自我效能感是否影响临床孤立综合征和早期复发缓解型多发性硬化症患者的认知表现?

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-04-29 DOI: 10.1155/2015/960282

Peter Joseph Jongen, Keith Wesnes, Björn van Geel, Paul Pop, Hans Schrijver, Leo H Visser, H Jacobus Gilhuis, Ludovicus G Sinnige, Augustina M Brands

{"title":"Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis?","authors":"Peter Joseph Jongen, Keith Wesnes, Björn van Geel, Paul Pop, Hans Schrijver, Leo H Visser, H Jacobus Gilhuis, Ludovicus G Sinnige, Augustina M Brands","doi":"10.1155/2015/960282","DOIUrl":"https://doi.org/10.1155/2015/960282","url":null,"abstract":"In persons with multiple sclerosis (MS) a lowered self-efficacy negatively affects physical activities. Against this background we studied the relationship between self-efficacy and cognitive performance in the early stages of MS. Thirty-three patients with Clinically Isolated Syndrome (CIS) and early Relapsing Remitting MS (eRRMS) were assessed for self-efficacy (MSSES-18), cognition (CDR System), fatigue (MFIS-5), depressive symptoms (BDI), disease impact (MSIS-29), and disability (EDSS). Correlative analyses were performed between self-efficacy and cognitive scores, and stepwise regression analyses identified predictors of cognition and self-efficacy. Good correlations existed between total self-efficacy and Power of Attention (r= 0.65; P< 0.001), Reaction Time Variability (r= 0.57; P< 0.001), and Speed of Memory (r= 0.53; P< 0.01), and between control self-efficacy and Reaction Time Variability (r= 0.55; P< 0.01). Total self-efficacy predicted 40% of Power of Attention, 34% of Reaction Time Variability, and 40% of Speed of Memory variabilities. Disease impact predicted 65% of total self-efficacy and 58% of control self-efficacy variabilities. The findings may suggest that in persons with CIS and eRRMS self-efficacy may positively affect cognitive performance and that prevention of disease activity may preserve self-efficacy. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"960282"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/960282","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33379066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Development of Activity-Related Muscle Fatigue during Robot-Mediated Upper Limb Rehabilitation Training in Persons with Multiple Sclerosis: A Pilot Trial. 多发性硬化症患者在机器人介导的上肢康复训练中活动相关肌肉疲劳的发展:一项试点试验。

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-05-24 DOI: 10.1155/2015/650431

Johanna Renny Octavia, Peter Feys, Karin Coninx

{"title":"Development of Activity-Related Muscle Fatigue during Robot-Mediated Upper Limb Rehabilitation Training in Persons with Multiple Sclerosis: A Pilot Trial.","authors":"Johanna Renny Octavia, Peter Feys, Karin Coninx","doi":"10.1155/2015/650431","DOIUrl":"https://doi.org/10.1155/2015/650431","url":null,"abstract":"Robot-assisted rehabilitation facilitates high-intensity training of the impaired upper limb in neurological rehabilitation. It has been clinically observed that persons with Multiple Sclerosis (MS) have difficulties in sustaining the training intensity during a session due to the development of activity-related muscle fatigue. An experimental observational pilot study was conducted to examine whether or not the muscle fatigue develops in MS patients during one session of robot-assisted training within a virtual learning environment. Six MS patients with upper limb impairment (motricity index ranging from 50 to 91/100) and six healthy persons completed five training bouts of three minutes each performing lifting tasks, while EMG signals of anterior deltoid and lower trapezius muscles were measured and their subjective perceptions on muscle fatigue were registered. Decreased performance and higher subjective fatigue perception were present in the MS group. Increased mean EMG amplitudes and subjective perception levels on muscle fatigue were observed in both groups. Muscle fatigue development during 15' training has been demonstrated in the arm of MS patients, which influences the sustainability of training intensity in MS patients. To optimize the training performance, adaptivity based on the detection of MS patient's muscle fatigue could be provided by means of training program adjustment. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"650431"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/650431","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33402958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study. 疾病改善药物减少复发缓解型多发性硬化症皮质病变积累和萎缩进展:一项为期48个月的扩展研究的结果

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-02-23 DOI: 10.1155/2015/369348

Francesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, Paolo Gallo

{"title":"Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study.","authors":"Francesca Rinaldi, Paola Perini, Matteo Atzori, Alice Favaretto, Dario Seppi, Paolo Gallo","doi":"10.1155/2015/369348","DOIUrl":"https://doi.org/10.1155/2015/369348","url":null,"abstract":"Cortical lesions (CLs) and atrophy are pivotal in multiple sclerosis (MS) pathology. This study determined the effect of disease modifying drugs (DMDs) on CL development and cortical atrophy progression in patients with relapsing-remitting MS (RRMS) over 48 months. Patients (n = 165) were randomized to sc IFN β-1a 44 μg, im IFN β-1a 30 μg, or glatiramer acetate 20 mg. The reference population comprised 50 DMD-untreated patients with RRMS. After 24 months, 43 of the untreated patients switched to DMDs. The four groups of patients were followed up for an additional 24 months. At 48 months the mean standard deviation number of new CLs was significantly lower in patients treated with sc IFN β-1a (1.4 ± 1.0, range 0–5) compared with im IFN β-1a (2.3 ± 1.3, range 0–6, P = 0.004) and glatiramer acetate (2.2 ± 1.5, range 0–7, P = 0.03). Significant reductions in CL accumulation and new white matter and gadolinium-enhancing lesions were also observed in the 43 patients who switched to DMDs after 24 months, compared with the 24 months of no treatment. Concluding, this study confirms that DMDs significantly reduce CL development and cortical atrophy progression compared with no treatment.","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"369348"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/369348","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33156374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 12

Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis. 多发性硬化症患者的抗癫痫和抗抑郁综合用药。

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-06-29 DOI: 10.1155/2015/317859

Georg Anton Giæver Beiske, Trygve Holmøy, Antonie Giæver Beiske, Svein I Johannessen, Cecilie Johannessen Landmark

{"title":"Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.","authors":"Georg Anton Giæver Beiske, Trygve Holmøy, Antonie Giæver Beiske, Svein I Johannessen, Cecilie Johannessen Landmark","doi":"10.1155/2015/317859","DOIUrl":"https://doi.org/10.1155/2015/317859","url":null,"abstract":"Objective. Patients with multiple sclerosis (MS) are often suffering from neuropathic pain. Antiepileptic drugs (AEDs) and tricyclic antidepressants (TCAs) are commonly used and are susceptible to be involved in drug interactions. The aim of this retrospective study was to investigate the prevalence of use of antiepileptic and antidepressive drugs in MS patients and to discuss the theoretical potential for interactions. Methods. Review of the medical records from all patients treated at a dedicated MS rehabilitation centre in Norway between 2009 and 2012. Results. In total 1090 patients attended a rehabilitation stay during the study period. Of these, 342 (31%; 249 females) with mean age of 53 (±10) years and EDSS 4.8 (±1.7) used at least one AED (gabapentin 12.7%, pregabalin 7.7%, clonazepam 7.8%, and carbamazepine 2.6%) or amitriptyline (9.7%). Polypharmacy was widespread (mean 5.4 drugs) with 60% using additional CNS-active drugs with a propensity to be involved in interactions. Age, gender, and EDSS scores did not differ significantly between those using and not using AED/amitriptyline. Conclusion. One-third of MS patients attending a rehabilitation stay receive AED/amitriptyline treatment. The high prevalence of polypharmacy and use of CNS-active drugs calls for awareness of especially pharmacodynamic interactions and possible excessive adverse effects. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"317859"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/317859","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33878459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care. 多发性硬化症复发的生活经历:多发性硬化症成人如何处理他们的复发经历并评估他们对复发后护理的需求。

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-05-13 DOI: 10.1155/2015/351416

Miho Asano, Karli Hawken, Merrill Turpin, Abby Eitzen, Marcia Finlayson

{"title":"The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care.","authors":"Miho Asano, Karli Hawken, Merrill Turpin, Abby Eitzen, Marcia Finlayson","doi":"10.1155/2015/351416","DOIUrl":"https://doi.org/10.1155/2015/351416","url":null,"abstract":"Background. Multiple sclerosis (MS) relapses can take a toll on individuals' health and quality of life. Given such consequences of relapses, postrelapse care beyond pharmacological approaches may play an important role in recovery. Nevertheless, how individuals with MS process their relapse experience and manage the consequences is still uncertain. Purpose. We conducted a qualitative study to understand relapse experiences and postrelapse care need from perspectives of adults with MS and identify relapse management patterns. Methods. We interviewed 17 adults with MS. Results. By examining combinations of three categories related to relapse experience, we identified four relapse management patterns: (i) Active Relapse Manager, (ii) Early-Stage Proactive Relapse Monitor, (iii) Adapted Passive Relapse Manager, and (iv) Passive Relapse Monitor. The relapse management patterns appear to associate strongly with the appraisal of the experience. Conclusions. The results of this study suggest the importance of understanding each patient beyond their functional limitations and the potential need for multidisciplinary postrelapse care which goes past restoring functional limitations at the acute phase. Future research to further understand the relapse management process at all stages of the healthcare continuum is a crucial step toward developing strategies to advance the current postrelapse care and to facilitate optimal recovery. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"351416"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/351416","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33263389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Prevalence of Depression and Anxiety among Patients with Multiple Sclerosis Attending the MS Clinic at Sheikh Khalifa Medical City, UAE: Cross-Sectional Study. 阿联酋谢赫哈利法医疗城多发性硬化症门诊患者抑郁和焦虑的患病率:横断面研究

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-07-09 DOI: 10.1155/2015/487159

Taoufik Alsaadi, Khadija El Hammasi, Tarek M Shahrour, Mustafa Shakra, Lamya Turkawi, Abdulla Mudhafar, Lina Diab, Mufeed Raoof

引用次数: 31

Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. 鞘内IgG合成:未来多发性硬化症治疗的一个耐药和有价值的靶点。

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-01-08 DOI: 10.1155/2015/296184

Mickael Bonnan

{"title":"Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.","authors":"Mickael Bonnan","doi":"10.1155/2015/296184","DOIUrl":"https://doi.org/10.1155/2015/296184","url":null,"abstract":"Intrathecal IgG synthesis is a key biological feature of multiple sclerosis (MS). When acquired early, it persists over time. A growing body of evidence suggests that intrathecal Ig-secreting cells may be pathogenic either by a direct action of toxic IgG or by locally secreting bystander toxic products. Intrathecal IgG synthesis depends on the presence of CNS lymphoid organs, which are strongly linked at anatomical level to cortical subpial lesions and at clinical level to the impairment slope in progressive MS. As a consequence, targeting CNS lymphoid lesions could be a valuable new target in MS, especially during the progressive phase. As intrathecal IgGs are end-products of these lymphoid lesions, intrathecal IgG synthesis may be considered as a specific marker of the persistence of these inflammatory lesions. Here we review the effect upon intrathecal IgG synthesis of all drugs ever used in MS. Except for steroids, all these therapeutic strategies, including rituximab, failed to decrease intrathecal IgG synthesis, with the exception of a questionable incomplete action of natalizumab. Thus, IgG synthesis is a robust marker of persistent intrathecal inflammation and its complete normalization should be one of the goals in future therapeutic strategies. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"296184"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/296184","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33030113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 43

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. 芬戈莫德治疗复发-缓解型多发性硬化症患者:一项前瞻性观察性多中心上市后研究

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-07-22 DOI: 10.1155/2015/763418

Rocco Totaro, Caterina Di Carmine, Gianfranco Costantino, Roberta Fantozzi, Paolo Bellantonio, Aurora Fuiani, Ciro Mundi, Stefano Ruggieri, Carmine Marini, Antonio Carolei

{"title":"Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.","authors":"Rocco Totaro, Caterina Di Carmine, Gianfranco Costantino, Roberta Fantozzi, Paolo Bellantonio, Aurora Fuiani, Ciro Mundi, Stefano Ruggieri, Carmine Marini, Antonio Carolei","doi":"10.1155/2015/763418","DOIUrl":"https://doi.org/10.1155/2015/763418","url":null,"abstract":"Objective. The aim of this prospective observational multicenter postmarketing study was to evaluate fingolimod efficacy in a real world clinical setting. Methods. One hundred forty-two subjects with relapsing-remitting multiple sclerosis (RRMS) were enrolled in three multiple sclerosis centers throughout Central and Southern Italy between January 2011 and September 2013. After enrollment, regular visits and EDSS assessment were scheduled every 3 months, and MRI scan was obtained every 12 months. Patients were followed up from 1 to 33 months (mean 14.95 ± 9.15 months). The main efficacy endpoints included the proportion of patients free from clinical relapses, from disability progression, from magnetic resonance imaging activity, and from any disease activity. Results. Out of 142 patients enrolled in the study, 88.1% were free from clinical relapse and 69.0% were free from disability progression; 68.5% of patients remained free from new or newly enlarging T2 lesions and 81.7% of patients were free from gadolinium enhancing lesions. Overall the proportion of patients free from any disease activity was 41.9%. Conclusions. Our data in a real world cohort are consistent with previous findings that yield convincing evidence for the efficacy of fingolimod in patients with RRMS. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"763418"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/763418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33982588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials. 将开源分割算法应用于多发性硬化症患者和健康对照者的不同 OCT 设备：临床试验的意义

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-05-18 DOI: 10.1155/2015/136295

Pavan Bhargava, Andrew Lang, Omar Al-Louzi, Aaron Carass, Jerry Prince, Peter A Calabresi, Shiv Saidha

{"title":"Applying an Open-Source Segmentation Algorithm to Different OCT Devices in Multiple Sclerosis Patients and Healthy Controls: Implications for Clinical Trials.","authors":"Pavan Bhargava, Andrew Lang, Omar Al-Louzi, Aaron Carass, Jerry Prince, Peter A Calabresi, Shiv Saidha","doi":"10.1155/2015/136295","DOIUrl":"10.1155/2015/136295","url":null,"abstract":"Background. The lack of segmentation algorithms operative across optical coherence tomography (OCT) platforms hinders utility of retinal layer measures in MS trials. Objective. To determine cross-sectional and longitudinal agreement of retinal layer thicknesses derived from an open-source, fully-automated, segmentation algorithm, applied to two spectral-domain OCT devices. Methods. Cirrus HD-OCT and Spectralis OCT macular scans from 68 MS patients and 22 healthy controls were segmented. A longitudinal cohort comprising 51 subjects (mean follow-up: 1.4 ± 0.9 years) was also examined. Bland-Altman analyses and interscanner agreement indices were utilized to assess agreement between scanners. Results. Low mean differences (-2.16 to 0.26 μm) and narrow limits of agreement (LOA) were noted for ganglion cell and inner and outer nuclear layer thicknesses cross-sectionally. Longitudinally we found low mean differences (-0.195 to 0.21 μm) for changes in all layers, with wider LOA. Comparisons of rate of change in layer thicknesses over time revealed consistent results between the platforms. Conclusions. Retinal thickness measures for the majority of the retinal layers agree well cross-sectionally and longitudinally between the two scanners at the cohort level, with greater variability at the individual level. This open-source segmentation algorithm enables combining data from different OCT platforms, broadening utilization of OCT as an outcome measure in MS trials. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"136295"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33402957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Italian validation of the 12-item multiple sclerosis walking scale. 意大利对12项多发性硬化症步行量表的验证。

IF 2.5

Multiple Sclerosis International Pub Date : 2015-01-01 Epub Date: 2015-03-26 DOI: 10.1155/2015/540828

C Solaro, E Trabucco, A Signori, M Cella, M Messmer Uccelli, G Brichetto, P Cavalla, M Gironi, F Patti, L Prosperini

{"title":"Italian validation of the 12-item multiple sclerosis walking scale.","authors":"C Solaro, E Trabucco, A Signori, M Cella, M Messmer Uccelli, G Brichetto, P Cavalla, M Gironi, F Patti, L Prosperini","doi":"10.1155/2015/540828","DOIUrl":"https://doi.org/10.1155/2015/540828","url":null,"abstract":"Objective. Gait impairment is commonly in people with multiple sclerosis (MS). The 12-item MS walking scale (MSWS-12) assesses patients' measurement of walking quality. The aim of this study was to cross-culturally adapt and validate the MSWS-12 for the Italian population with MS. Methods. Six MS out-patient clinics across Italy enrolled subjects between June 2013 and December 2013. Construct validity of MSWS-12 was determined by examining correlations with the Italian version of the EDSS, the timed 25-foot walk (T25FW), and the Fatigue Severity Scale (FSS). Results. 321 MS subjects were enrolled. Mean age was 47.55 years and mean disease duration was 13.8 years. Mean EDSS score was 4.46. 185 subjects had a relapsing-remitting course, 92 were secondary progressive, 43 were primary progressive, and 1 had a clinically isolated syndrome. The mean total score of the MSWS-12 was 49.6 (SD: 31) with values ranging between 0 and 100. Correlations between the MSWS-12 with age, disease duration, and disease course were found but not with gender. Values of the MSWS-12/IT were significantly related to EDSS (0.71), to the T25FW (0.65), and to the FSS (0.51). Conclusion. MSWS-12/IT has been adapted and validated, it is a reliable and reproducible scale for Italian patients with MS. ","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":"2015 ","pages":"540828"},"PeriodicalIF":2.5,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2015/540828","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33227538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17